Company Overview and News

ADXS / Advaxis, Inc. null (Prospectus)

Filed Pursuant Rule 424(b)(5) Registration No.

ADXS / Advaxis, Inc. null (Prospectus)

2018-09-06 - 2
The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an off

Biotech Analysis Central Pharma News: MannKind's Agreement, Advaxis' Partnership, Sanofi's FDA Approval

2018-09-05 seekingalpha - 3
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.

Your Cancer Highlight: Advaxis Resurrects A 'Dead' Bone Cancer Program

2018-09-04 seekingalpha - 1
One of the core criticisms that shareholders of Advaxis (ADXS) have had with management of the company has been an inability to capitalize on seemingly promising clinical data, as programs using their attenuated listeria-based immunotherapy languish on the vine, unable (apparently) to gain the attention they need to secure lucrative funding.

ADXS / Advaxis, Inc. null

2018-08-23 - 1
As filed with the Securities and Exchange Commission on August 23, 2018

Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned

2018-07-31 seekingalpha - 3
Discussion: RedHill Biopharma’s (RDHL) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the data from placebo was achieved. The statistical difference was significant. Compared to the 23% remission, 37% patients in the drug-treatment group achieved remission at 26th week. Secondary endpoints were also met by the study. Maintenance of remission at 52nd week for those who achieved remission at 26th week was also reportedly superior for the drug over the placebo group.

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance

2018-07-31 seekingalpha - 1
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.

ADXS : Advaxis Stock Analysis and Research Report

2017-10-31 - Asif

Advaxis is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products with the lead program in Phase 3 development. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis will continue to invest in its core clinical franchises and will also remain opportunistic based on Investigator Sponsored Trials (“ISTs”) as well as licensing opportunities. ...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ADXS / Advaxis, Inc. on message board site Silicon Investor.

ADXS - Advaxis, Inc. (Bulls Board) ADXS - Advaxis, Inc. (Bulls Board) ADXS - Advaxis, Inc. (Bulls Board)
CUSIP: 007624208